^
    Back
    Association details:
    Biomarker:MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    High-Grade B-Cell Lymphomas with Translocations of MYC and BCL2 and/or BCL6 (Double/Triple Hit Lymphoma): Lisocabtagene maraleucel was added as a category 2A recommendation for relapsed/refractory disease.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet
    Title:

    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

    Published date:
    09/01/2020
    Excerpt:
    Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma)...an objective response was achieved by 186 (73%, 95% CI 66·8–78·0) patients and a complete response by 136 (53%, 46·8–59·4)....Use of liso-cel resulted in a high objective response rate, with a low incidence of grade 3 or worse cytokine release syndrome...
    DOI:
    10.1016/S0140-6736(20)31366-0
    Trial ID:
    TRANSCEND-NHL-001